Skip to main content
RAPS Euro Convergence 2026 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Learning Level: Advanced
Learning Level: Advanced
Learning Level: Expert
Learning Level: Expert
Learning Level: Foundational
Learning Level: Foundational
Learning Level: Intermediate
Learning Level: Intermediate
RAPS Focus
RAPS Focus
Networking Opportunity
Networking Opportunity
Ticketed Event
Ticketed Event
Student Focus
Student Focus
Evaluation ViewAttendees 4

Pharmaceuticals

Reimagining Europe's Innovation Landscape: Leveraging New Legislation to Accelerate Development and Maintain Competitiveness

Wednesday, May 6, 2026
08:30 - 09:30 WEST
Location: Pavilion 5
Description In this dynamic panel discussion, stakeholders from across the healthcare ecosystem will explore how Europe can strengthen its position as a hub for pharmaceutical innovation and development. Against the backdrop of evolving geopolitical challenges, the session will examine how new legislative and strategic frameworks - particularly the NPL, Biotech Act, Life Sciences Strategy, and EMANS to 2028 - can serve as enablers to enhance Europe's attractiveness for clinical research and innovative development approaches.

The discussion will focus on three critical areas: making Europe the clinical trial location of choice, supporting novel evidence generation methods (including AI and real-world evidence), and accelerating development through innovative regulatory science. Panelists will evaluate how these new policy frameworks can create favorable conditions for early-phase innovation while addressing broader European Commission priorities of maintaining global competitiveness.

With science advancing rapidly through innovative medicinal products and evolving development approaches, speakers will examine whether Europe's current policy trajectory effectively supports a more agile and innovative development ecosystem. The session will explore how stakeholders can leverage these new frameworks to create an environment that embraces novel methodologies, supports efficient clinical trial execution, and accelerates development timelines while maintaining European quality and safety standards.

This timely discussion will provide insights into practical opportunities for enhancing Europe's position in early-phase development, while considering how geopolitical challenges might impact implementation of these ambitious policy initiatives. The session will emphasize the importance of maintaining regulatory predictability while fostering innovation and ensuring Europe remains competitive in an increasingly complex global landscape.

Learning Objectives:

  • Evaluate how new legislative frameworks (Biotech Act, Life Sciences Strategy, NPL) can position Europe as the preferred destination for clinical trials and pharmaceutical innovation
  • Explore practical implementation strategies for novel evidence generation methods, including AI, real-world evidence, and innovative regulatory science approaches
  • Identify concrete actions stakeholders can take to accelerate development timelines while maintaining European quality and safety standards
  • Address geopolitical challenges and competitive pressures that may impact Europe's ability to attract and retain pharmaceutical innovation